Learn how complex synthetic medicines are reshaping drug development with precision-targeted therapies and global market momentum.
Categories
Tags
Analytical Chemistry
Analytical Science
Artificial Intelligence (AI)
Biocatalysis
Catalysis
CatSci Paper
CatSci Patent
Chemical Development
Complex Synthetic Medicines
Design of Experiments
Digital
Drug Development
Experimental Design
Green Chemistry
Industry insights
Innovation
Machine Learning (ML)
Material Science
Medium Throughput Experimentation
Oligonucleotides
Peptides
Principal Component Analysis
Process R&D
PROTACs
QbD
Route Scouting and Selection
Scale-up
Scavenging
Solvents
Sustainability
Technology transfer
Work-up
CatSci's Director of Analytical Science and Digital Transformation, Dr Sam Whitmarsh, participated in the latest Chemistry Today panel discussion on AI in Pharma Supply Chain. He discussed the impact of AI on Quality Control and Quality Assurance.
CatSci's Director of Chemical Sciences, Rob Crook, and Senior Scientist, Jean-Baptiste Vendeville discuss the current considerations needed when developing a synthesis for a HPAPI, as well as the challenges faced by these complex molecules, in particular ADCs.
Explore our interactive infographic to discover how you can leverage our process and tools to conduct a rigorous, objective route assessment that improves the scalability, efficiency, sustainability and quality of your synthesis
Explore our interactive infographic to find out what you need to consider for each phase of development and get one step ahead with your molecule.
ADLIB Recruitment spoke with CatSci CEO Dr Ross Burn as part of their Product | People | Potential series, showcasing entrepreneurs and businesses shaking up their sector.
CatSci's Senior Scientist, Dr Alice Dunbabin, participated in the latest Chemistry Today panel discussion on Catalysis.
CatSci's Director of New Modalities, Dr Nigel Richardson, participated in the latest Chemistry Today panel discussion on Oligonucleotides.
Our CEO, Dr Ross Burn discusses how pivoting in-line with the market's needs and having big aims of becoming an innovative medicines development partner led to business growth.
Our Talent Lead and Equality and Diversity Champion, York discusses his career journey and offers valuable advice to early career seekers and shifters.
Our CCO, Dr Simon Tyler, argues that to achieve true sustainability, a more holistic approach to overall drug development is needed.
The broader suite of computer-aided synthesis planning tools is increasingly catching up with chemists in its ability to establish the most suitable way of putting together a target active pharmaceutical ingredient.
Our Talent Lead, Seb York discusses how employers need to create an inclusive and supportive environment for their teams
Technology transfer is full of risks. But risks can be mitigated with the right strategy and help from digital technologies.
Speed and efficiency are everything in pharmaceutical synthesis – and that’s why biocatalysis is an increasingly attractive option.
Dr Alan Steven explains why environmental sustainability and “big picture thinking” should be key considerations when selecting solvents for scale-up.
Our CEO, Dr Ross Burn talks about surviving and thriving as a new company focused on process chemistry, alongside more recent moves into industry 4.0 and collaborations in the contract research space.
Our Chief Operating Officer, Dr Simon Tyler participated in the latest Chemistry Today panel discussion on custom synthesis and contract manufacturing.
Our Associate Principal Scientist, Dr Vargini Thangavadivale participated in the latest Chemistry Today panel discussion on catalysis
Our CEO, Dr Ross Burn talked to Chemicals Knowledge Hub TV about the origins of CatSci, our strategic shift and exponential growth over the past few years.
Our Chief Operating Officer, Dr Simon Tyler, recently spoke with The Medicine Maker to discuss the continuing impacts of COVID-19 on the pharmaceutical industry